Pneumocystis jirovecii infection (PJP) is a common cause of pneumonia in patients with cancer-related immunosuppression. There are well-defined patients who are at risk of PJP due to the status of their underlying malignancy, treatment-related immunosuppression and/or concomitant use of corticosteroids. Prophylaxis is highly effective and should be given to all patients at moderate to high risk of PJP. Trimethoprim-sulfamethoxazole is the drug of choice for prophylaxis and treatment, although several alternative agents are available.
Keywords: Pneumocystis carinii; Pneumocystis jirovecii; haematological malignancy; prophylaxis; solid-organ tumour; treatment.
© 2014 The Authors; Internal Medicine Journal © 2014 Royal Australasian College of Physicians.